Phase III Prolia Trial Meets Endpoint in Clinical Fractures in Breast Cancer Patients

A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease

City of Hope has received a $150 million gift from entrepreneurs and philanthropists A. Emmet Stephenson Jr. and his daughter Tessa Stephenson Brand to create a program focused on pancreatic cancer research.

September 17, 2024

By Paul Goldberg

Karen Knudsen to leave ACS

The American Cancer Society said that Karen E. Knudsen “announced her desire to transition” from her role as CEO of the 111-year-old charity in order to pursue “the next phase of her strategy to accelerate progress against cancer.”

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Tumors are able to form with no DNA mutations, fly study shows

Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.

Richard A. Rettig, author of an acclaimed history of the National Cancer Act, dies at 87

Richard A. Rettig, the author of an authoritative history of the writing of the National Cancer Act of 1971, died on Aug. 7.

From clinician scientist to nonprofit CEO

I was a practicing pediatric hematologist oncologist and researcher for 21 years. As a doctor, it was a tremendous privilege to be invited into the lives of patients and families dealing with blood cancers and be entrusted with their care. As a researcher, it was incredibly rewarding to help bring more effective blood cancer therapies to kids.

September 13, 2024

Vol.50 No.34

By E. Anders Kolb

Phase III Prolia Trial Meets Endpoint in Clinical Fractures in Breast Cancer Patients

YOU MAY BE INTERESTED IN

A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease

Karen Knudsen to leave ACS

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Tumors are able to form with no DNA mutations, fly study shows

Richard A. Rettig, author of an acclaimed history of the National Cancer Act, dies at 87

From clinician scientist to nonprofit CEO

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Phase III Prolia Trial Meets Endpoint in Clinical Fractures in Breast Cancer Patients

YOU MAY BE INTERESTED IN

A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease

Karen Knudsen to leave ACS

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Tumors are able to form with no DNA mutations, fly study shows

Richard A. Rettig, author of an acclaimed history of the National Cancer Act, dies at 87

From clinician scientist to nonprofit CEO

Can you spare 10 minutes to complete a survey?

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies